ES2184121T3 - Formulacion para el tratamiento y/o profilaxis de la demencia. - Google Patents

Formulacion para el tratamiento y/o profilaxis de la demencia.

Info

Publication number
ES2184121T3
ES2184121T3 ES97934492T ES97934492T ES2184121T3 ES 2184121 T3 ES2184121 T3 ES 2184121T3 ES 97934492 T ES97934492 T ES 97934492T ES 97934492 T ES97934492 T ES 97934492T ES 2184121 T3 ES2184121 T3 ES 2184121T3
Authority
ES
Spain
Prior art keywords
profilaxis
dementia
treatment
formulation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97934492T
Other languages
English (en)
Inventor
Schie Dirk M J Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2184121T3 publication Critical patent/ES2184121T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICION FARMACEUTICA PARA ADMINISTRACION CUTANEA, QUE COMPRENDE [R - (Z)] - AL - (METOXIIMINO) - AL - (1 AZABICICLO[2.2.2]OCT - 3 - IL)ACETONITRILO, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, JUNTO CON UN VEHICULO ADECUADO, FARMACEUTICAMENTE ACEPTABLE, PARA EL TRATAMIENTO O LA PROFILAXIS DE LA DEMENCIA.
ES97934492T 1996-07-25 1997-07-14 Formulacion para el tratamiento y/o profilaxis de la demencia. Expired - Lifetime ES2184121T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9615628.6A GB9615628D0 (en) 1996-07-25 1996-07-25 Formulation

Publications (1)

Publication Number Publication Date
ES2184121T3 true ES2184121T3 (es) 2003-04-01

Family

ID=10797487

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97934492T Expired - Lifetime ES2184121T3 (es) 1996-07-25 1997-07-14 Formulacion para el tratamiento y/o profilaxis de la demencia.

Country Status (23)

Country Link
EP (1) EP0918521B1 (es)
JP (1) JP2000515868A (es)
KR (1) KR20000029523A (es)
CN (1) CN1226163A (es)
AR (1) AR007983A1 (es)
AT (1) ATE224711T1 (es)
BR (1) BR9710546A (es)
CA (1) CA2261233A1 (es)
CO (1) CO5031290A1 (es)
CZ (1) CZ22799A3 (es)
DE (1) DE69715878T2 (es)
DK (1) DK0918521T3 (es)
ES (1) ES2184121T3 (es)
GB (1) GB9615628D0 (es)
IL (1) IL128095A (es)
NO (1) NO990283L (es)
NZ (1) NZ333704A (es)
PL (1) PL331283A1 (es)
PT (1) PT918521E (es)
TR (1) TR199900141T2 (es)
TW (1) TW426514B (es)
WO (1) WO1998004258A1 (es)
ZA (1) ZA976592B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
CN1221516C (zh) * 2000-09-27 2005-10-05 Dsmip财产有限公司 共轭二烯羰基化的方法
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy
CN109988144B (zh) 2017-12-29 2024-07-05 广州再极医药科技有限公司 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用
WO2026018154A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with non-cns penetrant muscarinic antagonists
WO2026018155A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
DE19501022C1 (de) * 1995-01-14 1996-06-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
DE69715878D1 (de) 2002-10-31
EP0918521A1 (en) 1999-06-02
CZ22799A3 (cs) 1999-06-16
DK0918521T3 (da) 2003-02-03
AU3768497A (en) 1998-02-20
KR20000029523A (ko) 2000-05-25
IL128095A (en) 2002-07-25
BR9710546A (pt) 1999-08-17
DE69715878T2 (de) 2003-05-22
CN1226163A (zh) 1999-08-18
AU721101B2 (en) 2000-06-22
ZA976592B (en) 1999-03-04
TW426514B (en) 2001-03-21
NZ333704A (en) 2000-06-23
WO1998004258A1 (en) 1998-02-05
TR199900141T2 (xx) 1999-03-22
CA2261233A1 (en) 1998-02-05
AR007983A1 (es) 1999-11-24
NO990283L (no) 1999-03-19
EP0918521B1 (en) 2002-09-25
IL128095A0 (en) 1999-11-30
JP2000515868A (ja) 2000-11-28
CO5031290A1 (es) 2001-04-27
HK1021314A1 (en) 2000-06-09
PT918521E (pt) 2003-02-28
ATE224711T1 (de) 2002-10-15
GB9615628D0 (en) 1996-09-04
NO990283D0 (no) 1999-01-22
PL331283A1 (en) 1999-07-05

Similar Documents

Publication Publication Date Title
BG101118A (en) Therapeutical compounds
MY118151A (en) Pharmaceutical formulations containing voriconazole.
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
GT199800126A (es) Terapia de combinacion.
IL131651A0 (en) A pharmaceutical formulation containing benzimidazoles with amino acid/caclodextrin combinations and a process for producing the same
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
RU95106362A (ru) Производные липопептида, способ их получения, содержащая их фармацевтическая композиция и способ ее получения
CA2194167A1 (en) Hair-growing agent
CA2043033A1 (fr) Utilisation du baclofene pour l'obtention de medicaments destines au traitement de l'angine de poitrine
IL98310A0 (en) The pharmacological use of certain cystine derivatives
WO1997018790A3 (en) Therapeutic and diagnostic agents for the treatment of microbial infections
MX9200728A (es) Formulacion farmaceutica adaptada para administracformulacion farmaceutica adaptada para administracion topica, para desordenes en la piel. ion topica, para desordenes en la piel.
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
AU4445089A (en) Lactamimides in the treatment of drug-resistant protozoal infections
RU94040150A (ru) Стабильная лиофилизированная композиция тиотепа, способ ее получения
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
ES2122085T3 (es) Combinacion antibiotica.
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
BG106151A (en) Pharmaceutical complex